- KSQ-001EX is an investigational eTIL therapy manufactured using our ExPRESS™ process in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing.
- KSQ’s Immune CRISPRomics® platform identified SOCS1 as a top target, constraining TIL anti-tumor function, engraftment, and persistence.
- The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase 1/2 clinical study of KSQ-001EX.
